Search

Your search keyword '"Revel T"' showing total 322 results

Search Constraints

Start Over You searched for: Author "Revel T" Remove constraint Author: "Revel T"
322 results on '"Revel T"'

Search Results

2. A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study

5. Double Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study from the SFGM-TC

13. OUTCOMES OF CORD BLOOD TRANSPLANTATION USING REDUCED INTENSITY CONDITIONING REGIMEN FOR CHRONIC LYMPHOCITYC LEUKEMIA: A RETROSPECTIVE STUDY ON BEHALF OF EUROCORD, SFGM-TC AND CMWP-EBMT: PH-P087

14. Effect of priming with granulocyte–macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group

19. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM)

20. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation

21. Granulocyte–macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial)

22. The survival after allogeneic stem cell transplantation for blast crisis chronic myelogenous leukaemia relies on disease status prior to transplant and on the EBMT score, in the tyrosine kinase inhibitors era: P1150

25. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

26. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial

29. HLA disparity, cell dose and age as risk factors for DFS in cord blood transplantation after non-myeloablative conditioning in 112 adults with haematological malignancies. A French multicentre study of the SFGM-TC and Eurocord

31. Etude multi-échelle du matériau SiC-SiC / MI et application sur pièces aéronautiques

36. S115 IMPACT OF MESURABLE RESIDUAL DISEASE POSITIVITY ON OUTCOMES FOLLOWING UNMBILICAL CORD BLOOD TRANSPLANTATION: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT AND EUROCORD

39. CARFILZOMIB WEEKLY PLUS MELPHALAN AND PREDNISONE IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA (IFM 2012-03) / 21st Congress of the European-Hematology-Association

41. Granulocytic Sarcoma in a Nonleukemic Patient: Place of Radiotherapy and Systemic Therapies

42. Impact of Response in Patients (Pts) With Stem Cell Transplant (SCT)-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Treated With Continuous Lenalidomide + Low-Dose Dexamethasone (Rd) in the FIRST Trial

43. Treatment of radiation burns with surgery and cell therapy. A report of two cases [Irradiation aiguë localisée: Chirurgie et thérapie cellulaire. A propos de deux cas]

46. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

47. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

49. Activités physiques et hémopathies malignes: le rôle du médecin du sport.

Catalog

Books, media, physical & digital resources